|
|
Article: MabCure Inc. Featured in GEN Genetic Engineering & Biotechnology News.
- Article from:
- Cancer Weekly
- Article date:
- September 22, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MabCure, Inc. ("MabCure"), a diagnostic company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, is featured in the September issue of GEN (Genetic Engineering & Biotechnology News). The article, written by MabCure CEO, Dr. Amnon Gonenne, entitled "Searching for Appropriate Cancer Biomarkers," describes how tumor-specific antibodies could positively impact diagnosis, imaging, and therapy (see also MabCure, Inc.).
"Cancer biomarker discovery has been hampered by the heterogeneity of the diseases known as cancer," Dr. Gonenne writes. "Even within one cancer type, for example breast, several distinct ...
Related newspaper, magazine, and journal articles:
|
|
Article: Mabcure, Inc. Featured in BioWorld[R] Today.
Business Wire;
August 25, 2009 ;
700+ words
... ... to Seek Cancer Antigens HASSELT, Belgium -- MabCure, Inc. (OTCBB:MBCI) ("MabCure"), a biotechnology company using its proprietary ... story, written by Jennifer Boggs and titled "MabCure's Revamped Hybridoma Approach Seeks Cancer ...
|
|